A single arm, interventional study with 12 weeks study phase preceded by a 2-week run in phase, aiming to evaluate the effectiveness and applicability of the Tandem Mobi automated insulin delivery system (Tandem Mobi Pump System) for competitive youth athletes with type 1 diabetes in real-world conditions.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
12
Tandem Mobi Hybrid Closed Loop (HCL) pump with an integrated Control-IQ algorithm (CIQ), the Dexcom G7 continuous glucose monitoring sensor (CGM ) and Tandem Mobi Mobile App
Schneider Children's Medical Center of Israel
Petah Tikva, Israel
Sensor glucose percentage of time in range (70-180 mg/dl)
Time frame: At the end of the 12 weeks intervention period
Percentage of sensor glucose readings <54 mg/dl
Time frame: At the end of the 12 weeks intervention period
Percentage of sensor glucose readings >180 mg/dl
Time frame: At the end of the 12 weeks intervention period
Percentage of sensor glucose readings >250 mg/dl
Time frame: At the end of the 12 weeks intervention period
HbA1c
Time frame: At the end of the 12 weeks intervention period
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.